Health Observance

National Influenza Vaccination Week

John Arnst
Dec. 2, 2019

The year may be winding down, but flu season is still heating up. If you’ve been slacking on getting your annual shot, it’s not too late — in fact, the Centers for Disease Control and Prevention designated the first week of December as National Influenza Vaccination Week. While the flu vaccine remains the best line of defense against the fever, fatigue and range of respiratory symptoms of a genuine influenza infection, ASBMB members have been investigating how influenza viruses interact with our cells and uncovering leads for new antivirals and improved vaccines.

Why glycosylation matters in building a better flu vaccine

If influenza viruses were DNA-based, we may well have developed a universal vaccine decades ago. But, as retroviruses, they have a tendency to rack up errors every time they replicate, gradually changing the makeup of their hemagglutinin and neuraminidase proteins and slipping ever beyond the protective yoke of each season’s vaccine. While efforts to develop a universal flu vaccine are under way at labs around the world, flu vaccine design processes currently don’t account for the glycosylation that influenza A viruses, the primary cause of human influenza illnesses, use to evade host antibodies. Deborah Chang and Joseph Zaia at Boston University recently made the case in the journal Molecular & Cellular Proteomics that developing methods to determine site-specific glycosylation of glycoproteins in influenza A viruses could enhance the efficacy of future flu vaccines.

Forever in search of new antivirals

Developing new antivirals can feel like an exercise in futility — just over a year after the drug Xofluza was approved for distribution in the United States, scientists at the University of Wisconsin–Madison found that influenza viruses in a quarter of patients who took the drug developed resistance to it. While few drugs make it all the way through the development pipeline, biochemists are regularly discovering compounds that can take advantage of novel mechanisms to inhibit viral replication.

Histone deacetylases play a role in preventing influenza replication

Like almost all viruses, influenza A viruses hijack host machinery to replicate. In response to evidence that an optimal acetylation environment in host cells is favorable to this process, researchers at the University of Otago in New Zealand investigated the effects of histone deacetylases, which negatively regulate acetylation, against IAVs.

Influenza viruses love lipids

After influenza has hijacked a host cell’s machinery to crank out its RNA and proteins, it needs to get them wrapped in a protective lipid envelope so that new virions can venture forth and infect more host cells. Researchers at the University of Singapore recently used a mass spectrometry-based lipidomics approach to investigate how IAVs interact with the host cells’ lipid metabolism during different stages of infection. They found that function of membrane-bound peroxisomes to be a common metabolic denominator and a potential key determinant for influenza virus replication.

Gut microbes, glycosphingolipids and influenza

Invariant natural killer T cells are versatile — they thwart tumors, attack pathogenic bacteria viruses and play a role in autoimmune diseases — and the glycosphingolipid α-galactosylceramide, produced by Bacteroides in the human gut, is key to their activation. Researchers at the University of Marburg and German Cancer Research Center recently found that conditions including colitis, consumption of a Western diet and infection by influenza A virus tend to decrease levels of αGalCer. This suggests that modulating gut microbial-derived immunogenic lipids including αGalCerML may impact immunity.

Hosts and their viruses: a thematic series of review articles

Hot off the heels of the swine flu epidemic — an H5N1 strain from the antigenic shift that happened when two starkly different influenza strains infected the same pig population — Charles Samuel helped organize a JBC minireview series with the aim of understanding the structural basis for interactions between influenza viruses and host cells. Read the series.

John Arnst

John Arnst was a science writer for ASBMB Today.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

DNA and COVID-19: What’s the connection?
Observance

DNA and COVID-19: What’s the connection?

April 23, 2021

Studies have linked virus susceptibility and severity to genes inherited from Neanderthals and to blood type — but not all researchers agree on the results.

A celebration of our other genome: Mitochondrial DNA
Observance

A celebration of our other genome: Mitochondrial DNA

April 22, 2021

The genes in human mtDNA encode some essential components of the electron transport chain, as well as a set of tRNAs and ribosomal RNAs necessary for protein synthesis.

Eternal memories and an overdue tribute — storing digital data in DNA
Art

Eternal memories and an overdue tribute — storing digital data in DNA

April 21, 2021

Researchers crowdsourced 10,000 images, stored them on synthetic DNA and then used them to create a portrait of Rosalind Franklin, an often overlooked star of DNA discovery.

Genetic research in the midst of a pandemic
Observance

Genetic research in the midst of a pandemic

April 20, 2021

A study in the United Kingdom has identified four novel genetic variants associated with critical illness in patients with COVID-19.

Scientists unmask a virus that mimicked human RNA and hit on a potential vaccine
News

Scientists unmask a virus that mimicked human RNA and hit on a potential vaccine

April 18, 2021

Human metapneumovirus is a molecular mimic, sneaking past immune systems to cause cold symptoms

Synthesis of potent antibiotic follows unusual chemical pathway
News

Synthesis of potent antibiotic follows unusual chemical pathway

April 17, 2021

Images of a protein involved in creating a potent antibiotic reveal the unusual first steps of the antibiotic's synthesis.